Codexis, Inc. (CDXS)
CDXS Price and Sentiment
CDXS Latest news
REDWOOD CITY, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in three upcoming virtual investment conferences.
Codexis (CDXS) delivered earnings and revenue surprises of 133.33% and 27.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Codexis' (CDXS) CEO John Nicols on Q3 2021 Results - Earnings Call Transcript
Record Quarterly Total Revenue, Product Revenue and Product Gross Margin Reiterating Total Revenue Guidance of $98-103M; Raising Product Revenue Guidance to $63-66M
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REDWOOD CITY, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the third quarter of 2021 on Thursday, November 4, 2021, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update.
Codexis is leveraging its core technology to create more effective life science tools.
Codexis, Almelo and RC2 Announce a Tri-Party Collaboration for the Enzymatic Production of Low Cost Sitagliptin API for the Generic Market, Including a License to Codexis Enzyme Technology in India2021-10-18 08:00
REDWOOD CITY, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced a tri-party collaboration agreement with Almelo Private, Ltd., an Indian producer of active pharmaceutical ingredients (APIs), and RC2 Pharma Connect, LLC, a U.S.-based leading pharmaceutical manufacturing representative, to license and manufacture for internal use a Codexis' proprietary enzyme used in the manufacturing process for sitagliptin, a leading API in the treatment of diabetes. Under the agreement, Almelo will be responsible for the development, scale-up, and establishment of a commercial manufacturing process for sitagliptin incorporating Codexis' proprietary enzyme technology. Upon completion, the enzyme's manufacturing will be established at Almelo's API manufacturing site to enable further cost reduction. RC2's role in the collaboration will be to leverage its relationships with global drug product partners to establish do
If you are looking for stocks that are well positioned to maintain their recent uptrend, Codexis (CDXS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Codexis (CDXS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.